You are here
AdvaMedDx Commends Increased Investment in Precision Medicine
WASHINGTON, D.C. – Andrew Fish, executive director of AdvaMedDx, issued the following statement today in response to President Barack Obama’s newly announced Precision Medicine Initiative:
“We appreciate the Administration’s support for increased investments in precision medicine. Innovations in diagnostic tests, including genetic sequencing technologies, are a cornerstone of precision medicine. Diagnostic tests are the key to ensuring the right treatment for the right patient at the right time. AdvaMedDx member companies are the innovators whose technologies are providing incredible insights and revolutionizing health care. We look forward to working with the White House, NIH, FDA, and Congress on this important initiative.”
AdvaMedDx member companies produce innovative, safe and effective in vitro diagnostic tests that facilitate evidence-based medicine, improve quality of patient care, promote wellness, enable early detection of disease and reduce overall health care costs. Functioning as an association within AdvaMed, AdvaMedDx is dedicated to the issues facing in vitro diagnostic companies both in the United States and abroad.